Recurrent B Acute Lymphoblastic Leukemia: Clinical Trials

21 trials for Recurrent B Acute Lymphoblastic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 recruiting, 5 terminated, 4 withdrawn, 3 active not recruiting. 21 Phase 1, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 121Recruiting 6, Terminated 5, Withdrawn 4, Active not recruiting 3, Completed 3
Phase 29Withdrawn 4, Terminated 3, Active not recruiting 1, Recruiting 1

Follow Recurrent B Acute Lymphoblastic Leukemia: new trials by email Literature Review of Recurrent B Acute Lymphoblastic Leukemia trials Research Report on Recurrent B Acute Lymphoblastic Leukemia

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 1RecruitingCity of Hope Medical Center162027-04-172026-11-13
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Biospecimen Collection, Pomalidomide - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1RecruitingUniversity of Michigan Rogel Cancer Center122026-08-262026-10-15
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Phase 1RecruitingCity of Hope Medical Center262026-05-132026-10-16
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
Fludarabine, Cyclophosphamide, Mesna - Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia
Phase 1RecruitingSt. Jude Children's Research Hospital302025-04-282026-05-19
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2WithdrawnFred Hutchinson Cancer Center2025-04-012024-07-12
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Phase 1 / Phase 2WithdrawnChildren's Oncology Group2023-08-012023-09-01
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Phase 1Active not recruitingOHSU Knight Cancer Institute202022-09-022026-05-06
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Phase 1RecruitingSumithira Vasu542022-06-302026-05-29
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center42022-02-172025-08-11
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells
Phase 1 / Phase 2WithdrawnRoswell Park Cancer Institute2021-01-212022-01-28
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Phase 1CompletedCity of Hope Medical Center132020-11-182026-01-28
CD19-Specific T Cells Post AlloSCT
Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia
Phase 1TerminatedM.D. Anderson Cancer Center42020-06-262021-06-02
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Etoposide, Doxorubicin, Vincristine - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 1CompletedUniversity of Washington242019-09-242023-07-06
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2019-05-152023-08-21
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center532019-04-032026-05-13
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center372018-08-242025-12-12
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Biospecimen Collection, Computed Tomography, Lumbar Puncture - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingECOG-ACRIN Cancer Research Group402018-08-132026-10-06
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Palbociclib, Dexamethasone - Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Phase 1CompletedSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University72018-05-092025-05-15
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, Cyclophosphamide, Fludarabine - Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1TerminatedFred Hutchinson Cancer Center552017-11-032024-04-10
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Phase 1Active not recruitingNational Cancer Institute (NCI)282017-10-252026-11-18

Showing 20 of 21. Sign in to see all of them.

Narrower conditions

Burkitt Lymphoma (21)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (5)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (5)  ·  Leukemia, Biphenotypic, Acute (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Lymphoma, B-Cell (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Disease Progression (1)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Hairy Cell (1)

Broader conditions

DNA Virus Infections (21)  ·  Epstein-Barr Virus Infections (21)  ·  Hemic and Lymphatic Diseases (21)  ·  Herpesviridae Infections (21)  ·  Immune System Diseases (21)  ·  Immunoproliferative Disorders (21)  ·  Infections (21)  ·  Lymphatic Diseases (21)  ·  Lymphoma (21)  ·  Lymphoproliferative Disorders (21)  ·  Neoplasms (21)  ·  Neoplasms by Histologic Type (21)  ·  Tumor Virus Infections (21)  ·  Virus Diseases (21)  ·  Lymphoma, B-Cell (18)

Interventions

Cyclophosphamide (11)  ·  Biopsy (7)  ·  Specimen Handling (7)  ·  Vincristine (7)  ·  Dexamethasone (5)  ·  Methotrexate (5)  ·  Prednisone (5)  ·  fludarabine (5)  ·  Calcium Dobesilate (4)  ·  Cytarabine (4)  ·  Rituximab (4)  ·  Spinal Puncture (4)  ·  blinatumomab (4)  ·  merphos (4)  ·  venetoclax (4)

Sponsors

M.D. Anderson Cancer Center (6)  ·  City of Hope Medical Center (3)  ·  Fred Hutchinson Cancer Center (2)  ·  Children's Oncology Group (1)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  National Cancer Institute (NCI) (1)  ·  OHSU Knight Cancer Institute (1)  ·  Roswell Park Cancer Institute (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)  ·  St. Jude Children's Research Hospital (1)  ·  Sumithira Vasu (1)  ·  University of Michigan Rogel Cancer Center (1)  ·  University of Washington (1)

Countries

United States (20)  ·  Puerto Rico (1)

Top investigators

Jordan Gauthier (2)  ·  Amandeep Salhotra (1)  ·  Elias Jabbour (1)  ·  Elias Jabbour, MD (1)  ·  Eunice S Wang (1)  ·  Ibrahim Aldoss (1)  ·  Ibrahim T Aldoss (1)  ·  Ivana Gojo (1)  ·  Jennifer E Agrusa, MD (1)  ·  Jessica T Leonard (1)  ·  Jin S Im (1)  ·  Margaret Kasner, MD (1)  ·  Matthew A Kutny (1)  ·  Neil D Palmisiano (1)  ·  Nicholas Short, MD (1)

Results publications

PMID 35622074, PMID 28859185, PMID 29352703, PMID 34515338, PMID 37131217, PMID 37187201, PMID 38207208, PMID 38324336, PMID 38551807, PMID 38722664, PMID 39415930, PMID 39820359, PMID 41671463

NIH funding

P30CA033572 (3), P30CA016672 (1), R01CA276374 (1), U10CA180820 (1), U10CA180886 (1), UM1CA186691 (1)